The advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) for the treatment of advanced non-small cell lung cancer has resulted in an increasing number of long-term survivors. Consequently, the emergence of second malignancy may have implications for their prognosis. This study found that 8.9% of patients with advanced NSCLC who received TKIs, ICIs, or immune combination therapy and survived ≥ 2 years developed second malignancy. It was suggested that by performing screening and examinations for the second malignancy, both malignancies could be controlled.

The miR-1307-3p has oncogenic activity, as it leads to a decrease in PRM2 expression in breast cancer cells, which in turn promotes the proliferation of this pathology by inducing processes such as proliferation, migration, invasion, and angiogenesis.

We conducted a meta-analysis to evaluate the efficacy of prophylactic cranial irradiation (PCI) in resected small-cell lung cancer (SCLC) patients. The use of PCI delayed brain recurrence and improved overall survival in patients with resected, stage I–III SCLC. Importantly, patients with N0 SCLC can also benefit from postoperative PCI.

Sex-determining region Y-related high-mobility group box 17 protein (SOX17) immunoreactivity was observed in TECs with high endothelial venule (HEV) features, including a plump, almost cuboidal appearance of varying degrees (a). SOX17 immunoreactivity was nonuniform and rather heterogenous even in adjacent endothelial cells (black and white arrows indicate robust and weak SOX17 immunoreactivity, respectively). The numerous red-stained CD8⁺ T lymphocytes present around the SOX17-positive HEVs are notable.

The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced NSCLC.

This report describes a 60-year-old man with stage IIIA (cT2N2M0) lung adenocarcinoma harboring a METex14 skipping mutation. After initial treatment with savolitinib was discontinued due to grade 4 transaminitis, the patient was switched to tepotinib. Six months later, significant tumor shrinkage was observed, and surgery revealed remarkable pathological response with no residual tumor in lymph nodes (ypT2N0M0, IB). Postoperative tepotinib continued, with no relapse at 6-month follow-up. The arrows in different colors highlight different involved sites: yellow arrows — primary tumor lesion; red arrows — 7th lymph node; blue arrows — right hilar lymph node.